Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: A prospective, single-center cohort study in Chinese living-related kidney transplantation

Transplant Infectious Disease

Volumn 16, Issue 5, 2014, Pages 760-766

  Fu, L ^a   Huang, Z ^a   Song, T ^a   He, S ^a   Zeng, D ^a   Rao, Z ^a   Xie, L ^a   Song, Y ^a   Wang, L ^a   Lin, T ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Area under curve; Infection; Kidney transplant; Mycophenolate mofetil; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

COTRIMOXAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; CHINESE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG TREATMENT FAILURE; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BACTERIAL INFECTIONS; BLOOD; CHINA; GRAFT SURVIVAL; LONGITUDINAL STUDY; MYCOSES; SURVIVAL RATE; TIME; TREATMENT FAILURE; YOUNG ADULT;

ADULT; AREA UNDER CURVE; BACTERIAL INFECTIONS; CHINA; DRUG MONITORING; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MYCOPHENOLIC ACID; MYCOSES; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84907961448     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12275     Document Type: Article

References (26)

1. Guerra G, Ciancio G, Gaynor JJ, et al. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol 2011; 22: 1758-1768.
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13-58.
3. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534-542.
4. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant 2009; 9: 1495-1499.
5. Shaw LM, Nicholls A, Hale M, Meiser B, van Gelder T. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998; 31: 317-322.
6. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-315.
7. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145-154.
8. Saint-Marcoux F, Vandierdonck S, Prémaud A, Debord J, Rousseau A, Marquet P. Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther Drug Monit 2011; 33: 285-294.
9. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 2002; 13: 759-768.
10. Le Meur Y, Thierry A, Caillard S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496-2503.
11. Kuypers DR, de Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008; 30: 673-683.
12. Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006; 6: 121-128.
13. Mourad M, Malaise J, Chaib Eddour D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 88-94.
14. de Winter BC, Mathot RA, Sombogaard F, Vulto AG, van Gelder T. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol 2011; 6: 656-663.
15. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455.
16. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043-1051.
17. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009; 9: 1607-1619.
18. Le Meur Y, Thierry A, Glowacki F, et al. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Transplantation 2011; 92: 1244-1251.
19. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497-1504.
20. Wang X, Qin X, Wang Y, et al. Controlled-dose versus fixed-dose mycophenolate mofetil for kidney transplant recipients: a systematic review and meta-analysis of randomized controlled trials. Transplantation 2013; 96: 361-367.
21. Zicheng Y, Peijun Z, Da X, Xianghui W, Hongzhuan C. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol 2006; 62 (4): 446-452.
22. Jiao Z, Zhong JY, Zhang M, Shi XJ, Yu YQ, Lu WY. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol 2007; 63: 27-37.
23. Cho EK, Han DJ, Oh JM, et al. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol 2004; 44: 743-750.
24. Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc 2004; 36: 2076-2078.
25. Clayton PA, McDonald SP, Chapman JR, Chadban SJ. Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial. Transplantation 2012; 94: 152-158.
26. Glander P, Sommerer C, Arns W, et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010; 5: 503-511.